Table 2

Characteristics of HCV study population

Received HCV treatment during study period


Total (n = 7411)

Yes (n = 3469)

No (n = 3942)

n

%

n

%

n

%


Gender

Female

2750

37.1

1134

32.7

1616

41.0

Male

4661

62.9

2335

67.3

2326

59.0

Age category

0-19

18

0.2

3

0.1

15

0.4

10-19

51

0.7

18

0.5

33

0.8

20-29

142

1.9

55

1.6

87

2.2

30-39

716

9.7

342

9.9

374

9.5

40-49

3194

43.1

1583

45.6

1611

40.9

50-59

2714

36.6

1294

37.3

1420

36.0

60-64

329

4.4

137

3.9

192

4.9

65+

247

3.3

37

1.1

210

5.3

Census Region

Midwest

305

4.1

142

4.1

163

4.1

Northeast

4730

63.8

2259

65.1

2471

62.7

South

700

9.4

368

10.6

332

8.4

West

369

5.0

134

3.9

235

6.0

Othera

1307

17.6

566

16.3

741

18.8

Health insurance typeb

Health Maintainance Organization

3247

43.8

1500

43.2

1747

44.3

Individual Plans

302

4.1

142

4.1

16.

4.1

Point of Service

755

10.2

382

11.0

373

9.5

Preferred Provider Organization

2914

39.3

1405

40.5

1509

38.3

Other

167

2.3

39

1.1

128

3.2

Advanced liver disease

1462

19.7

1017

29.3

445

11.3

Cirrhosis

1335

18.0

926

26.7

409

10.4

Hepatocellular carcinoma

127

1.7

91

2.6

36

0.9

Drug use

1101

14.9

447

12.9

654

16.6

Alcohol use

485

6.5

166

4.8

319

8.1


a Other region includes other regions and regions which were masked for confidentiality purposes

b 26 patients had unknown health insurance type.

Louie et al. BMC Infectious Diseases 2012 12:86   doi:10.1186/1471-2334-12-86

Open Data